ArticleFrontiers in medicine2025
Absence of progression risk of chronic kidney disease in patients with urine protein-creatinine ratio below 500 mg/g: a cohort study with competing risk analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Albumin/creatinine ratio thresholds associated with poor sleep quality in elderly obese non-diabetic individuals: a cross-sectional study.BMC nephrology · 2026Article
- International Environmental Impact of CKD Care.Kidney international reports · 2026Article
- Plasma Thrombospondin-1 in Etiology-Specific Associations with Proteinuria Events in Pediatric Chronic Kidney Disease.Children (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies demonstrated a connection between minimal albuminuria and the progression of kidney disease, offering insights on the ideal threshold for antiproteinuric treatment. However, Limited data exist regarding the association between Urine Protein-Creatinine Ratio (UPCR) < 500 mg/g and Chronic Kidney Disease (CKD) progression, particularly in the context of competitive risk analysis. We aimed to investigate the correlation between UPCR and the progression of CKD in patients with UPCR below 500 mg/g. Methods: Initially, 512 patients diagnosed with stages G2-G5 of CKD and UPCR levels below 1,000 mg/g were recruited from the CKD-ROUTE cohort. Subsequently, patients with UPCR levels below 500 mg/g underwent further analysis. The Cox proportional hazards model and the competing risk model was utilized. Results: Over a median follow-up of 3.0 years, 24 out of 512 participants experienced progression of CKD. The current study revealed that compared to UPCR levels of 0-300 mg/g, patients with UPCR levels between 700 and 1,000 mg/g had a HR of 4.6 (95% CI 1.8-12.0%, Conclusion: In patients with CKD and UPCR levels below 500 mg/g, there was no increased risk of CKD progression associated with the higher proteinuria levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.